glucose, (beta-d)-isomer has been researched along with apremilast in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adams, M; Baillie, GS; Bartlett, JB; Capone, L; Cheung, YF; Gandhi, AK; Gilhar, A; Houslay, MD; Loveland, MA; Man, HW; Muller, GW; Parton, A; Schafer, PH; Stirling, DI; Wu, L | 1 |
| Sigler, J | 1 |
| Hussar, DA | 1 |
3 other study(ies) available for glucose, (beta-d)-isomer and apremilast
| Article | Year |
|---|---|
Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.
Topics: Administration, Oral; Adult; Animals; Anti-Inflammatory Agents; Cell Proliferation; Cyclic Nucleotide Phosphodiesterases, Type 4; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Enterotoxins; Gene Expression Regulation; Humans; Inflammation Mediators; Keratinocytes; Killer Cells, Natural; Leukocytes, Mononuclear; Lipopolysaccharides; Mice; Mice, SCID; Middle Aged; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Psoriasis; RNA, Messenger; Severity of Illness Index; Skin; Skin Transplantation; Thalidomide; Time Factors; Transplantation, Heterologous; U937 Cells; Ultraviolet Rays; Zymosan | 2010 |
Drug updates and approvals: 2014 in review.
Topics: Allergens; Benzhydryl Compounds; Benzyl Alcohols; Chlorobenzenes; Drug Approval; Dry Powder Inhalers; Glucagon-Like Peptide 1; Glucosides; Humans; Insulin; Lactones; Nurse Practitioners; Phleum; Plant Extracts; Pollen; Pyrazoles; Pyridines; Pyrimidines; Quinuclidines; Thalidomide; United States; United States Food and Drug Administration | 2014 |
New drugs 2015, part 1.
Topics: Benzhydryl Compounds; Benzyl Alcohols; Chlorobenzenes; Dibenzazepines; Drug Approval; Estrogens, Conjugated (USP); Glucosides; Humans; Indoles; Nitriles; Pyridones; Pyrimidines; Quinuclidines; Thalidomide; United States; United States Food and Drug Administration | 2015 |